For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Kura Oncology Inc’s stock clocked out at $9.14, down -0.65% from its previous closing price of $9.2. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 1.95 million shares were traded. KURA stock price reached its highest trading level at $9.372 during the session, while it also had its lowest trading level at $9.07.
Ratios:
To gain a deeper understanding of KURA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.26 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.46. For the most recent quarter (mrq), Quick Ratio is recorded 6.16 and its Current Ratio is at 6.16. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.UBS initiated its Buy rating on October 24, 2024, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 29 ’25 when WILSON TROY EDWARD bought 36,615 shares for $9.05 per share.
LEONI MOLLIE bought 12,314 shares of KURA for $111,442 on Sep 29 ’25. On Sep 29 ’25, another insider, POWL BRIAN T, who serves as the Officer of the company, bought 8,891 shares for $9.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 793326272 and an Enterprise Value of 182071264. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.53 while its Price-to-Book (P/B) ratio in mrq is 2.60. Its current Enterprise Value per Revenue stands at 2.186 whereas that against EBITDA is -0.832.
Stock Price History:
The Beta on a monthly basis for KURA is 0.33, which has changed by -0.49334812 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $19.73, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 21.68%, while the 200-Day Moving Average is calculated to be 27.74%.
Shares Statistics:
It appears that KURA traded 1.65M shares on average per day over the past three months and 1830630 shares per day over the past ten days. A total of 86.80M shares are outstanding, with a floating share count of 84.12M. Insiders hold about 3.09% of the company’s shares, while institutions hold 93.65% stake in the company. Shares short for KURA as of 1757894400 were 10849204 with a Short Ratio of 6.57, compared to 1755216000 on 7996034. Therefore, it implies a Short% of Shares Outstanding of 10849204 and a Short% of Float of 12.529999.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is -$0.16, with high estimates of $0.65 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$0.4 and -$3.39 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$2.24, with 9.0 analysts recommending between -$0.37 and -$4.93.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $453.9M, while the lowest revenue estimate was $29.4M, resulting in an average revenue estimate of $148.79M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $201.18M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
